Immunovant
IMVT
Immunovant (IMVT) news
Recent news
Immunovant shares down 2% after co to stop development of imvt-1402 in Cle
AInvest Wire · Sep 23, 2026Immunovant shares down 6.7% premarket after co to stop development of imvt-1402 in Cle
Immunovant Inc. (IMVT) shares fell 6.7% in premarket trading on September 23, 2026, following the company’s announcement that it will discontinue the development of its drug candidate IMVT-1402 in the Cleveland (Cle) region. The decision marks a strategic shift for the biopharmaceutical firm, which…
AInvest Wire · Sep 23, 2026Immunovant: All other clinical development timelines remain on track
AInvest Wire · Sep 23, 2026Immunovant, - IMVT-1402 demonstrates favorable safety and tolerability profile
AInvest Wire · Sep 23, 2026Immunovant, - IMVT-1402 study in Cle did not achieve statistical significance on primary endpoint
AInvest Wire · Sep 23, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.